Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Creative Commons License

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...More

ANNALS OF NEUROLOGY, vol.77, no.3, pp.425-435, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 77 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.1002/ana.24339
  • Journal Name: ANNALS OF NEUROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.425-435
  • Karadeniz Technical University Affiliated: Yes

Abstract

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.